The difference between entrectinib and larotinib

Entrectinib and larotrectinib are two targeted therapies used to treat certain types of cancer. Although they have similar mechanisms of action and uses, there are some key differences between them, including targeted genes, clinical indications, drug metabolism, and adverse reactions. Here's a detailed comparison of the two drugs:

1.Targeted genes:

Enrectinib: Entrectinib mainly targets cancer cells carrying ALK (tyrosine kinase) and ROS1 (ROS1tyrosine kinase) fusion mutations. It inhibits the proliferation and growth of tumor cells by inhibiting these abnormally activated fusion proteins and blocking related signaling pathways.

Larotinib: Larotinib mainly targets the fusion mutation ofTRK (neurotrophic factor receptor) gene. Fusion mutations of the TRK gene can lead to the production of abnormally activated TRK fusion proteins, promoting the occurrence and development of tumors. Larotrectinib inhibits the growth of tumors by inhibiting these abnormally activated fusion proteins and blocking related signaling pathways.

2.Clinical indications:

Enrectinib: Entrectinib is indicated for the treatment of ALK and ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other locally advanced or metastatic solid tumors. It has been approved for specific types of cancer, such as NSCLC, gastrointestinal tumors, breast cancer, pancreatic cancer, and others.

Larotinib: Larotinib is suitable for the treatment of any solid tumor carryingTRK gene fusion mutations, including but not limited to breast cancer, lung cancer, thyroid cancer, pancreatic cancer, etc. It is forTRKThe first gene fusionFDA approved drug, larotrectinib may be an effective treatment option for patients who carry this gene mutation.

3.Drug metabolism:

Enrectinib: Entrectinib is mainly metabolized by the liver, in which theCYP3Aenzyme system plays an important role. Therefore, concurrent use with inducers or inhibitors of the CYP3A enzyme may affect the metabolism and plasma concentrations of entrectinib.

Larotinib: The metabolic pathway of larotrectinib is mainly through the cytochrome P450 enzyme system such as CYP3A4 and CYP2C9. Similar to entrectinib, drug interactions related to these enzymes may affect the metabolism and efficacy of larotrectinib.

4.Adverse reactions:

Entrectinib: Common adverse reactions of entrectinib include fatigue, nausea, vomiting, diarrhea, headache, loss of appetite, rash, etc. In addition, entrectinib may also cause serious adverse reactions such as abnormal liver function, prolonged QT interval, and neurological toxicity.

Larotinib: Common adverse reactions of larotrectinib include fatigue, nausea, vomiting, diarrhea, headache, weight gain, etc. Adverse effects of larotrectinib are relatively few and generally mild compared with entrectinib.

To summarize, entrectinib and larotinib are two targeted therapies used to treat specific types of cancer. Although they have similar mechanisms of action, there are some obvious differences in terms of target genes, clinical indications, drug metabolism, and adverse reactions. Doctors should choose the most appropriate treatment plan based on the patient's specific situation and disease characteristics.